FDA批准库博多焦隐形眼镜
2020年2月5日美国食品和药物管理局（FDA）批准了CooperVision公司生产的新型Biofinity®toric多焦隐形眼镜。
备受期待的产品结合了CooperVision的Biofinity®复曲面和Biofinity®多焦的光学设计，为患者提供他们应得的散光和老视矫正。该公司计划在今年晚些时候向美国眼科护理专业人士提供这种镜片，随后将向其他市场推出。
Biofinity®toric镜片的可靠性能扩展到了老年患者，”Michele Andrews，CooperVision北美专业和学术事务部的高级主管说，“美国眼科护理专业人员很快就会有一个更好佩戴，更满意，并为新的散光眼镜佩戴者提供了阅读眼镜的替代品。这对眼科从业者和他们的病人来说是互利的。”
有关Biofinity®复曲面多焦镜头的镜头参数和其他细节将在未来几个月内公布。
原文：
FDA Approves New CooperVision Biofinity® toric multifocal Contact Lenses
February 05, 2020
SAN RAMON, Calif., February 5, 2020—The U.S. Food and Drug Administration (FDA) has granted CooperVision, Inc. approval for its new Biofinity® toric multifocal contact lenses.
The highly-anticipated product combines the proven optical designs of CooperVision’s Biofinity® toric—the most prescribed toric lens on the market1—and Biofinity® multifocal to provide patients with both the astigmatism and presbyopia vision correction they deserve. The company plans to make the lenses available to U.S. eye care professionals later this year, followed by other markets.
“Biofinity® toric multifocal extends the reliable performance of our Biofinity® toric lenses to presbyopic patients,” said Michele Andrews, OD, Senior Director, Professional and Academic Affairs, North America, CooperVision “U.S. eye care professionals will soon have an easy-to-fit, familiar lens design they can count on to keep current toric wearers satisfied in contact lenses for longer, and provide new astigmatic wearers an alternative to reading glasses. It’s a win-win for practitioners and their patients.”
Lens parameters and other details regarding Biofinity® toric multifocal will be made public in the coming months.
来源：库博光学 CooperVision